The short version: nearly all bulk peptide API [active pharmaceutical ingredient — the raw drug substance itself, before it is filled into vials] sold into the US market is synthesized overseas — China holds most of the capacity — then imported, filled, and labeled by domestic vendors.
Since September 2025, FDA's Import Alert 66-80 detains all imported GLP-1 bulk substances without examination unless the maker is on a green list that held just 19 firms worldwide at its 27 July 2026 revision, and that FDA revises without notice.
Whether your vendor's upstream supplier is real, registered, and exempt is checkable — from two public FDA files, in minutes.
- "US-based vendor" almost never means US-synthesized. It usually means US-filled and US-shipped — the powder is imported.
- Import Alert 66-80 flipped the default for GLP-1s: detention first, exemption only for green-listed makers. FDA evaluated 48 GLP-1 API sites and found 21% noncompliant.
- The green list is tiny — 19 firms worldwide at the 27 July 2026 revision, and FDA revises it without notice — it changed again on 21 August 2026. The firm names on the public page are redacted, and any count you read, this one included, is a snapshot. The workable test is FDA registration, which is public.
- A supplier with no FDA establishment registration cannot be green-listed. That check takes five minutes against a public file.
- "Full reship if seized" is a tell, not a service. It is a seizure-insurance policy priced into your vial.
The shape of the chain
Overseas factories synthesise the powder. US vendors import it, fill vials, and put their own name on the label.
Peptide synthesis at commercial scale is real industrial chemistry — solid-phase synthesis lines, HPLC purification, lyophilization, solvent handling, clean rooms. That capacity is concentrated in pharmaceutical manufacturing hubs, and the largest concentration by far is in China, with meaningful capacity in India and Europe.
A typical US research vendor does not run any of it. The vendor imports bulk lyophilized powder by the gram or kilogram, then fills vials, applies labels, and ships — sometimes with real quality steps in between, sometimes with none.
None of this is inherently scandalous. It is how most of the world's generic pharmaceuticals work too. The scandal potential lives in the gap between what the chain is and what the marketing says it is — and in this market, that gap is often the whole pitch.
Which is why the questions that matter are structural: who synthesized it, are they real, are they registered, and did anyone test the finished vial in the vendor's own name [that last one is the COA question — COA, certificate of analysis].
Import Alert 66-80
Since September 2025 FDA can hold imported GLP-1 powder at the border without opening the box. A short list of exempted manufacturers is the way around it.
In September 2025, FDA stood up Import Alert 66-80 — "Detention Without Physical Examination of Glucagon-Like Peptide-1 Receptor Agonist Bulk Drug Substances." Translated out of customs language: shipments of the raw powder can be held at the border by default, with the burden on the importer to demonstrate admissibility, rather than the agency needing to inspect and object shipment by shipment.
A major revision landed July 27, 2026. The mechanism deserves a careful read, because it inverts the default you probably assume:
- Detention is the default. All imported GLP-1 bulk drug substances can be detained without physical examination.
- The main route around it is the green list — firms that maintained an active FDA foreign establishment registration and handed FDA batch records, COAs, validation reports, and customer lists.
- The green list held 19 firms worldwide at the 27 July 2026 revision: twelve in China, two in India, and one each in Belgium, Canada, Denmark, Ireland, and Portugal. It was revised again on 21 August 2026, so check the alert for the current roster.
- The names are redacted on the public page. Only countries and product codes are visible — you cannot simply read the list and match your supplier against it.
Two more details from the alert are worth quoting because they describe this market with unusual precision. FDA evaluated 48 GLP-1 API sites and found 21% noncompliant with basic drug-quality requirements.
And the agency describes a specific evasion pattern it keeps encountering: "a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA's requests for records, and then deregister, all within a short period of time." Registration theater — put a real-looking FEI number [FDA Establishment Identifier, the unique number FDA assigns to a registered facility] on the sales deck, ship for a season, vanish before the records request lands.
Enforcement in this lane is active: FDA issued a warning letter to a Harbin-based biotech in May 2026 over GLP-1 import violations.
One step downstream
The alert stops bulk powder, not your vial. A vendor whose supplier is not exempt pays for that in reship guarantees, unlabelled parcels and crypto discounts.
Import Alert 66-80 covers bulk API entering the country, not the finished research vial you buy. But every US vendor selling GLP-class research compounds sits directly downstream of it.
A vendor whose upstream maker is green-listed has a stable, lawful import lane. A vendor whose upstream maker is not faces detained shipments — and the market's workarounds for that problem are exactly the red flags buyers keep being told to ignore:
- "100% delivery guarantee — full reship if lost or seized." A supplier pricing in seizures is telling you which side of the default they expect to land on.
- "Discreet packaging, no external labeling." Licensed API ships labeled with substance, lot, and manufacturer, and clears customs with a COA. Unlabeled is a posture, and it is not a quality posture.
- Crypto-only payment with a discount. Covered in depth in our payments report — the discount is the measured price of your chargeback rights.
The five-minute supplier check
The exempt list hides firm names, but FDA establishment registration is public — and no firm gets exempted without one.
Here is the part that makes this article practical rather than atmospheric. The green list's names are redacted — but its precondition is public and searchable.
The alert covers "registered foreign manufacturers," and green-list membership requires an active FDA foreign establishment registration with an FEI number. No registration, no green list. Registration is checkable by anyone, free, against two bulk files:
- The establishment registration file. FDA publishes the Drug Establishments Current Registration Site data — roughly ten thousand rows, downloadable. Search the company name and its variants. A genuine API maker appears with a full street address, an FEI number, and an operation type of API manufacture.
- The Drug Master File list. FDA's DMF list — about forty thousand rows — shows which firms have filed manufacturing dossiers. A DMF is a drug master file: a confidential manufacturing dossier lodged with FDA. Filing one is not an approval. Serious API makers accumulate DMFs; a firm claiming years of pharma manufacturing with zero is telling on itself.
And the single question that separates every tier of this market: ask the supplier for an FEI number and a DMF reference.
A real one supplies both on request, because both are ordinary credentials in legitimate pharmaceutical trade. Evasion, delay, or a photograph of an unrelated certificate answers the question just as clearly.
Practical caveat: Chinese corporate registries [Tianyancha, QCC, and similar] are largely inaccessible from US networks — geo-blocks and anti-bot walls.
If a vendor claims to have "verified" a supplier through them from the US, be skeptical of the claim. The FDA files are the reliable lane, and they are the ones that actually govern imports.
Read it like an auditor
Six signals separate a real API maker from a trading company with a website.
| signal | what a real API maker shows | what a reseller or ghost shows |
|---|---|---|
| Legal identity | Registered entity, street address, license numbers published on its own site | English-only site, no registered name, no address beyond a city |
| FDA footprint | FEI number + operation type on the public file; often DMFs | Zero rows in either file |
| Domain history | Domain age roughly matches the claimed corporate history | "Since 2018" on a domain registered months ago — check WHOIS |
| Certification language | "GMP-certified" with a cert number and issuing body | "GMP-standard facility" — unfalsifiable by design |
| Shipping posture | Labeled API, customs-cleared with COA documentation | Discreet packaging, reship guarantees, crypto discounts |
| Test data shape | Results vary by compound and lot, like real analytics | Everything passes at the same number, or grades from a source that rates everyone identically |
One more pattern worth naming, because it recurs constantly: the quality spread is the fingerprint.
When independent community testing of a "manufacturer" shows some compounds testing consistently strong while others from the same seller fail at high rates, that is the signature of a reseller aggregating different upstream factories — not one facility with one quality system.
A real manufacturer's quality is correlated across its catalog. A trader's is not.
What "US-made" actually claims
US synthesis and US fill are two different claims. Ask which one the vendor is making, then ask for the name behind it.
Import pressure on the GLP lane is pushing part of the market toward domestic synthesis and domestic fill, and "US-made" will increasingly appear as a selling point.
Treat the claim exactly the way you treat a COA: as a checkable document, not a vibe. US drug establishments register with FDA in the same public file as foreign ones.
A vendor claiming US synthesis should be able to say who synthesizes, and that name should resolve to a registered establishment.
A vendor claiming US fill-and-finish is making a smaller claim — still meaningful for handling and lead times, but it is not a synthesis claim, and honest vendors keep the two distinct.
What we'd tell a friend
Buy from vendors who document the chain instead of describing it. The finished-lot certificate in their own name is the one document you can hold.
Buy from vendors who treat the supply chain as something to document rather than something to romance.
The strongest vendors in this market can tell you, without flinching: where the powder originates, what arrives with it, and what testing happens after it becomes their lot — in their name, at a named lab.
That last document is the one you can hold. Our 2026 COA audit ranks vendors on exactly that, and the buying fundamentals put the whole sequence in order.
FAQ
Does Import Alert 66-80 apply to non-GLP peptides like BPC-157?
No — 66-80 is specific to GLP-1 receptor agonist bulk substances. Other peptides enter under the general import framework, where FDA action is possible but not default-on. The GLP lane is uniquely pressurized because of the commercial stakes around the approved drugs.
The practical consequence is that the green list gives you no leverage at all on a BPC-157 supplier: there is no exempt roster to be on, and no default detention to be exempted from.
What still works is the check underneath the alert. FDA establishment registration is public for every drug establishment, foreign and domestic, and so is the drug master file list.
A supplier of any compound either appears in those files with a street address, an FEI number and an operation type of API manufacture, or it does not. For non-GLP compounds, finished-lot testing in the vendor's own name is then doing all the quality work.
Is Chinese-synthesized peptide automatically low quality?
No. Twelve of the 19 green-listed GLP-1 firms are Chinese, and China hosts genuinely world-class peptide API makers with FDA inspection histories. Origin is not the variable that predicts quality — registration, documentation, and finished-lot testing are.
China holds the largest concentration of commercial peptide synthesis capacity, with meaningful capacity in India and Europe, and none of that is inherently scandalous: it is how most of the world's generic pharmaceuticals work too.
The green list makes the point itself. Alongside the twelve Chinese firms sit two in India and one each in Belgium, Canada, Denmark, Ireland and Portugal.
What separates a real API maker from a trading company with a website is the same in every country — a registered legal identity with a street address, an FEI number on the public FDA file, drug master files, labeled customs-cleared shipments, and test data that varies by compound and lot the way real analytics do.
What is an FEI number?
An FDA Establishment Identifier — the unique number FDA assigns to a registered facility. It is the anchor for inspection history and registration status, and a legitimate manufacturer provides it on request. You do not have to take the supplier's word for it.
FDA publishes the Drug Establishments Current Registration Site file, roughly ten thousand rows and downloadable, and a genuine API maker appears there with a full street address, an FEI number, and an operation type of API manufacture.
That check is free and takes five minutes. It matters because green-list membership under Import Alert 66-80 requires an active FDA foreign establishment registration: no registration, no green list.
Treat the number as a starting point rather than a verdict. FDA describes a recurring pattern of sites that register as GLP-1 API manufacturers, offer APIs for import, refuse records requests, then deregister within a short period.
Can a vendor be honest and still have an unregistered upstream supplier?
For non-GLP compounds, yes — plenty of the market runs on unregistered synthesis, and finished-lot testing in the vendor's own name is then doing all the quality work.
For GLP-class compounds after Import Alert 66-80, an unregistered upstream is a fragile position, and the workarounds it forces are the red flags listed above. A vendor whose upstream maker is green-listed has a stable, lawful import lane.
A vendor whose maker is not faces detained shipments, and the market prices that risk straight into the product: full reship if lost or seized, discreet packaging with no external labeling, crypto-only payment at a discount. None of those three is a service.
Licensed API ships labeled with substance, lot, and manufacturer, and clears customs with a certificate of analysis. The honest version of this position is a vendor who names the origin, says what arrives with it, and publishes finished-lot testing in their own name.
Where are most research peptides manufactured?
The overwhelming majority of bulk peptide API — active pharmaceutical ingredient, the raw drug substance before it is filled into vials — sold into the US research market is synthesized overseas, with China holding the largest share of capacity.
US vendors typically import bulk powder and fill, label, and distribute domestically. Commercial peptide synthesis is real industrial chemistry: solid-phase synthesis lines, HPLC purification, lyophilization, solvent handling, clean rooms.
That capacity concentrates in pharmaceutical manufacturing hubs, with meaningful volume in India and Europe alongside China. A typical US research vendor runs none of it.
The vendor imports bulk lyophilized powder by the gram or kilogram, fills vials, applies labels, and ships — sometimes with real quality steps in between, sometimes with none. So a US-based vendor is almost never a US-synthesized vendor. It usually means US-filled and US-shipped.
What is FDA Import Alert 66-80?
Import Alert 66-80 lets FDA detain all imported GLP-1 receptor agonist bulk drug substances without physical examination by default.
Translated out of customs language: shipments of the raw powder can be held at the border, with the burden on the importer to demonstrate admissibility, rather than the agency needing to inspect and object shipment by shipment.
The route around it is the so-called green list — firms that have given FDA batch records, COAs, and validation reports.
The list held 19 firms worldwide at its 27 July 2026 revision, and FDA revises it without notice — it was revised again on 21 August 2026, so read the alert itself for the current roster.
The firm names on the public page are redacted; only countries and product codes are visible. The alert covers bulk API entering the country, not the finished research vial.
How can I check whether a peptide supplier is FDA-registered?
Two public FDA files answer it in minutes: the Drug Establishments Current Registration Site file, which lists every registered establishment with address and FEI number, and the Drug Master File list.
A real API manufacturer appears in the registration file with a full street address and an operation type of API manufacture. No registration means the firm cannot be green-listed. The registration file runs to roughly ten thousand rows and is downloadable, so search the company name and its variants.
The drug master file list runs to about forty thousand rows and shows which firms have filed manufacturing dossiers with FDA. Filing one is not an approval, but serious API makers accumulate them.
Then ask the supplier directly for an FEI number and a DMF reference. A real manufacturer supplies both on request. Evasion, delay, or a photograph of an unrelated certificate answers the question just as clearly.
Is a reship guarantee from a peptide supplier a good sign?
No. A guarantee to fully reship packages lost or seized in customs prices seizure risk into the product.
Licensed API ships labeled with substance, lot, and manufacturer, and clears customs with a COA — it does not need a seizure insurance policy. The guarantee tells you which side of Import Alert 66-80 the supplier expects to land on.
Since September 2025 that alert detains imported GLP-1 bulk substances by default unless the maker sits on a green list that held 19 firms worldwide at its 27 July 2026 revision.
A supplier outside that lane absorbs detentions, and the market's workarounds show up together: full reship if lost or seized, discreet packaging with no external labeling, crypto-only payment at a discount. Read them as one posture rather than three perks. Not one of them is a quality posture.
References
- FDA Import Alert 66-80 — Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances — accessdata.fda.gov [original list September 2025; major revision July 27, 2026]
- FDA, Drug Establishments Current Registration Site [downloadable registration file] — fda.gov
- FDA, List of Drug Master Files — fda.gov
- FDA warning letters database [GLP-1 import enforcement, 2026] — fda.gov
disclosure: inside your peptides is published by the owners of the next lab, the only vendor we are paid by, including the next lab. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.